Your browser doesn't support javascript.
loading
Neuroendocrine Tumors of Unknown Primary in the Setting of Cytoreductive Hepatectomy.
Ammann, Markus; Gudmundsdottir, Hallbera; Hackl, Hubert; Antwi, Stella K Adjei; Santol, Jonas; Habermann, Elizabeth B; Thiels, Cornelius A; Warner, Susanne G; Truty, Mark J; Kendrick, Michael L; Smoot, Rory L; Nagorney, David M; Cleary, Sean P; Halfdanarson, Thorvardur R; Starlinger, Patrick P.
Afiliação
  • Ammann M; Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Mayo Clinic, Rochester, MN, USA.
  • Gudmundsdottir H; Department of Surgery, State Hospital Wiener Neustadt, Wiener Neustadt, Austria.
  • Hackl H; Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Mayo Clinic, Rochester, MN, USA.
  • Antwi SKA; Division of Health Care Delivery Research, Robert D. and Patricia E. Kern Center for Science of Health Care Delivery, Mayo Clinic, Rochester, MN, USA.
  • Santol J; Institute of Bioinformatics, Biocenter, Medical University of Innsbruck, Innsbruck, Austria.
  • Habermann EB; Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Mayo Clinic, Rochester, MN, USA.
  • Thiels CA; Department of Surgery, University Milano-Bicocca, Minao, Italy.
  • Warner SG; Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Mayo Clinic, Rochester, MN, USA.
  • Truty MJ; Department of Surgery, HPB Center, Vienna Health Network, Clinic Favoriten and Sigmund Freud Private University, Vienna, Austria.
  • Kendrick ML; Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Mayo Clinic, Rochester, MN, USA.
  • Smoot RL; Division of Health Care Delivery Research, Robert D. and Patricia E. Kern Center for Science of Health Care Delivery, Mayo Clinic, Rochester, MN, USA.
  • Nagorney DM; Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Mayo Clinic, Rochester, MN, USA.
  • Cleary SP; Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Mayo Clinic, Rochester, MN, USA.
  • Halfdanarson TR; Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Mayo Clinic, Rochester, MN, USA.
  • Starlinger PP; Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Mayo Clinic, Rochester, MN, USA.
Ann Surg Oncol ; 31(8): 4931-4941, 2024 Aug.
Article em En | MEDLINE | ID: mdl-38717544
ABSTRACT

BACKGROUND:

Surgical cytoreduction for neuroendocrine tumor liver metastasis (NETLM) consistently shows positive long-term outcomes. Despite reservations in guidelines for surgery when the primary tumor is unidentified (UP-NET), this study compared the surgical and oncologic long-term outcomes between patients with these rare cases undergoing cytoreductive surgery and patients who had liver resection for known primaries.

METHODS:

The study identified 32 unknown primary liver metastases (UP-NETLM) in 522 retrospectively evaluated patients who underwent resection of well-differentiated NETLM between January 2000 and December 2020. Tumor and patient characteristics were compared with those in 490 cases of liver metastasis from small intestinal (SI-NETLM) or pancreatic (pNETLM) primaries. Survival analysis was performed to highlight long-term outcome differences. Surgical outcomes were compared between liver resections alone and simultaneous primary resections to assess surgical risk distinctions.

RESULTS:

The UP-NET patients had fewer NETLMs (p = 0.004), which on the average were larger than SI-NETLMs or pNETLMs (p = 0.002). Expression of Ki-67 was balanced among the groups. Major hepatectomy was performed more often in the UP-NETLM group (p = 0.017). The 10-year survival rate of 53% for UP-NETLM was comparable with that for SI-NETML (58%; p = 0.463) and pNETLMs (47%; p = 0.497). The median hepatic progression-free survival was 26 months for the UP-NETLM patients and 25 months for the SI-NETLM patients compared to 12 months for the pNETLM patients (p < 0.001). Perioperative mortality was lower than 2%, and severe postoperative morbidity occurred in 21%, similarly distributed among all the groups.

CONCLUSION:

The surgical risk and long-term outcomes for the UP-NETLM patients were comparable with those for other NETLM cases, affirming the validity of equally aggressive surgical cytoreduction as a therapeutic option in carefully selected cases.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Primárias Desconhecidas / Tumores Neuroendócrinos / Procedimentos Cirúrgicos de Citorredução / Hepatectomia / Neoplasias Hepáticas Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Primárias Desconhecidas / Tumores Neuroendócrinos / Procedimentos Cirúrgicos de Citorredução / Hepatectomia / Neoplasias Hepáticas Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article